Mid-Term Assessment of the EU Drugs Strategy 2013-2020 and Final Evaluation of the Action Plan on Drugs 2013-2016

Public consultation on the evaluation of the EU Drugs Strategy: Report of results

by Jirka Taylor, Stijn Hoorens

Full Document

FormatFile SizeNotes
PDF file 1.1 MB

Use Adobe Acrobat Reader version 10 or higher for the best experience.

Research Questions

  1. Have measures been implemented to achieve the objectives in the EU Drugs Strategy and its Action Plan?
  2. How effective have the implemented measures been?
  3. What other steps should be taken to improve the drugs situation in the European Union?

A mandatory public consultation was conducted to inform the Mid-Term Assessment of the EU Drugs Strategy 2013-2020 and the final evaluation of the EU Action Plan on Drugs 2013-2016. This document reports on the consultation's results.

Table of Contents

  • Chapter One


  • Chapter Two

    Demographic profile of consultation respondents

  • Chapter Three


  • Chapter Four

    Other ad-hoc contributions

  • Annex One

    Additional tables

  • Annex Two

    Analysis framework for the public consultation

  • Annex Three

    Public consultation questionnaire

Research conducted by

The research described in this report was prepared for the European Commission and conducted by RAND Europe.

This report is part of the RAND Corporation Research report series. RAND reports present research findings and objective analysis that address the challenges facing the public and private sectors. All RAND reports undergo rigorous peer review to ensure high standards for research quality and objectivity.

The RAND Corporation is a nonprofit institution that helps improve policy and decisionmaking through research and analysis. RAND's publications do not necessarily reflect the opinions of its research clients and sponsors.